BACKGROUND: Physical inactivity triggers a rapid loss of muscle mass and function in older adults. Middle-aged adults show few phenotypic signs of aging yet may be more susceptible to inactivity than younger adults. OBJECTIVE: The aim was to determine whether leucine, a stimulator of translation initiation and skeletal muscle protein synthesis (MPS), can protect skeletal muscle health during bed rest. DESIGN: We used a randomized, double-blind, placebo-controlled trial to assess changes in skeletal MPS, cellular signaling, body composition, and skeletal muscle function in middle-aged adults (n = 19; age ± SEM: 52 ± 1 y) in response to leucine supplementation (LEU group: 0.06 g ∙ kg(-1) ∙ meal(-1)) or an alanine control (CON group) during 14 d of bed rest. RESULTS: Bed rest decreased postabsorptive MPS by 30% ± 9% (CON group) and by 10% ± 10% (LEUgroup) (main effect for time, P < 0.05), but no differences between groups with respect to pre-post changes (group × time interactions) were detected for MPS or cell signaling. Leucine protected knee extensor peak torque (CON compared with LEUgroup: -15% ± 2% and -7% ± 3%; group × time interaction, P < 0.05) and endurance (CON compared with LEU: -14% ± 3% and -2% ± 4%; group × time interaction, P < 0.05), prevented an increase in body fat percentage (group × time interaction, P < 0.05), and reduced whole-body lean mass loss after 7 d (CON compared with LEU: -1.5 ± 0.3 and -0.8 ± 0.3 kg; group × time interaction, P < 0.05) but not 14 d (CON compared with LEU: -1.5 ± 0.3 and -1.0 ± 0.3 kg) of bed rest. Leucine also maintained muscle quality (peak torque/kg leg lean mass) after 14 d of bed-rest inactivity (CON compared with LEU: -9% ± 2% and +1% ± 3%; group × time interaction, P < 0.05). CONCLUSIONS: Bed rest has a profoundly negative effect on muscle metabolism, mass, and function in middle-aged adults. Leucine supplementation may partially protect muscle health during relatively brief periods of physical inactivity. This trial was registered at clinicaltrials.gov as NCT00968344.
RCT Entities:
BACKGROUND: Physical inactivity triggers a rapid loss of muscle mass and function in older adults. Middle-aged adults show few phenotypic signs of aging yet may be more susceptible to inactivity than younger adults. OBJECTIVE: The aim was to determine whether leucine, a stimulator of translation initiation and skeletal muscle protein synthesis (MPS), can protect skeletal muscle health during bed rest. DESIGN: We used a randomized, double-blind, placebo-controlled trial to assess changes in skeletal MPS, cellular signaling, body composition, and skeletal muscle function in middle-aged adults (n = 19; age ± SEM: 52 ± 1 y) in response to leucine supplementation (LEU group: 0.06 g ∙ kg(-1) ∙ meal(-1)) or an alanine control (CON group) during 14 d of bed rest. RESULTS: Bed rest decreased postabsorptive MPS by 30% ± 9% (CON group) and by 10% ± 10% (LEU group) (main effect for time, P < 0.05), but no differences between groups with respect to pre-post changes (group × time interactions) were detected for MPS or cell signaling. Leucine protected knee extensor peak torque (CON compared with LEU group: -15% ± 2% and -7% ± 3%; group × time interaction, P < 0.05) and endurance (CON compared with LEU: -14% ± 3% and -2% ± 4%; group × time interaction, P < 0.05), prevented an increase in body fat percentage (group × time interaction, P < 0.05), and reduced whole-body lean mass loss after 7 d (CON compared with LEU: -1.5 ± 0.3 and -0.8 ± 0.3 kg; group × time interaction, P < 0.05) but not 14 d (CON compared with LEU: -1.5 ± 0.3 and -1.0 ± 0.3 kg) of bed rest. Leucine also maintained muscle quality (peak torque/kg leg lean mass) after 14 d of bed-rest inactivity (CON compared with LEU: -9% ± 2% and +1% ± 3%; group × time interaction, P < 0.05). CONCLUSIONS: Bed rest has a profoundly negative effect on muscle metabolism, mass, and function in middle-aged adults. Leucine supplementation may partially protect muscle health during relatively brief periods of physical inactivity. This trial was registered at clinicaltrials.gov as NCT00968344.
Authors: Hans C Dreyer; Satoshi Fujita; Jerson G Cadenas; David L Chinkes; Elena Volpi; Blake B Rasmussen Journal: J Physiol Date: 2006-07-27 Impact factor: 5.182
Authors: Robert H Coker; Nicholas P Hays; Rick H Williams; Robert R Wolfe; William J Evans Journal: J Gerontol A Biol Sci Med Sci Date: 2014-08-13 Impact factor: 6.053
Authors: C Suetta; L G Hvid; L Justesen; U Christensen; K Neergaard; L Simonsen; N Ortenblad; S P Magnusson; M Kjaer; P Aagaard Journal: J Appl Physiol (1985) Date: 2009-08-06
Authors: Roger A Vaughan; Randi Garcia-Smith; Nicholas P Gannon; Marco Bisoffi; Kristina A Trujillo; Carole A Conn Journal: Amino Acids Date: 2013-06-29 Impact factor: 3.520
Authors: Paul T Reidy; Alec I McKenzie; Preston Brunker; Daniel S Nelson; Katherine M Barrows; Mark Supiano; Paul C LaStayo; Micah J Drummond Journal: Rejuvenation Res Date: 2017-06-19 Impact factor: 4.663
Authors: Cameron J Mitchell; Randall F D'Souza; Sarah M Mitchell; Vandre C Figueiredo; Benjamin F Miller; Karyn L Hamilton; Fredrick F Peelor; Marcelli Coronet; Chantal A Pileggi; Brenan Durainayagam; Aaron C Fanning; Sally D Poppitt; David Cameron-Smith Journal: J Appl Physiol (1985) Date: 2017-11-09
Authors: Chris McGlory; Mark T von Allmen; Tanner Stokes; Robert W Morton; Amy J Hector; Briony A Lago; Amogelang R Raphenya; Brennan K Smith; Andrew G McArthur; Gregory R Steinberg; Steven K Baker; Stuart M Phillips Journal: J Gerontol A Biol Sci Med Sci Date: 2018-07-09 Impact factor: 6.053
Authors: Emily J Arentson-Lantz; Kinga N Fiebig; Kim J Anderson-Catania; Rachel R Deer; Adam Wacher; Christopher S Fry; Séverine Lamon; Douglas Paddon-Jones Journal: J Appl Physiol (1985) Date: 2020-03-19